This trial showed that the combination of lapatinib (an inhibitor of EGFR and HER2) with paclitaxel did not provide significant benefits to TNBC and HER2−progesterone receptor (PR) high patient groups but exhibited notable therapeutic advantages in other metastatic breast cancer cohorts [48, 49]. The gene discussed is EGFR; the disease is breast cancer.